Date Title & Summary Additional Formats
October 19, 2021
Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
PRINCETON, N.J. , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9 th , 2021.
October 12, 2021
Certara Appoints Patrick F. Smith to President of Integrated Drug Development
PRINCETON, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith , Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery . Dr.
October 5, 2021
Certara Appoints Drayton T. Virkler as Chief Commercial Officer
Experienced commercial leader brings 20 years of experience in pharma PRINCETON, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer.
October 4, 2021
Certara Completes Acquisition of Pinnacle 21
Complementary technologies accelerate and help assure success in the drug development process PRINCETON, N.J. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire
September 30, 2021
Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process
Cloud-based and validated regulatory software automates and advances quality of patient narratives PRINCETON, N.J. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the launch of Synchrogenix™ Writer, a new regulatory SaaS product that expedites the
September 22, 2021
Certara Announces New Clinical Science Group and Adds Senior Scientific Experts
Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities PRINCETON, N.J. , Sept. 22, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical science group,
September 20, 2021
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence PRINCETON, N.J. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S.
September 13, 2021
Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
PRINCETON, N.J. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the
September 8, 2021
Certara Announces Pricing of Public Offering of Common Stock
PRINCETON, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its common stock by Certara and certain existing stockholders (“the selling stockholders”) at a price to
September 3, 2021
Certara Announces Proposed Public Offering of Common Stock
PRINCETON, N.J. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange
Displaying 1 - 10 of 36